Guest Column

White Ash vs. Black Ash

Is the longstanding popular belief that white ash is ‘good’ nothing more than a myth?

7 Critical Questions Cannabis Businesses Need to Be Asking About The Corporate Transparency Act, The Most Important Federal Law You’ve Never Heard Of

Complying with the CTA, which took effect in 2024, can be deceptively complicated, and failure to do so can subject companies to civil—and even criminal—penalties.

Cannabis Reform Momentum Unprecedented in Recent Years

In the past three years, the federal government has taken steps to provide more access to research, rescheduling may be on the horizon and nearly half of U.S. states have legalized adult-use cannabis.

8 Tips to Maximize Cannabis Cultivation Energy Efficiency Rebates

RII expert members share tips and insights into getting the most out of programs that will help pay for facility upgrades.

7 Takeaways From the Feds' Cannabis Rescheduling Recommendation

Attorney Jonathan Havens outlines what stood out for him most after reviewing the 252-page document released by the U.S. Department of Health & Human Services.

A Positive Sign For Schedule III

In Vienna, a U.S. state department legal adviser champions member-state discretion over domestic drug policy, potentially removing the obstacle the Single Convention drug treaty could pose to cannabis reform.

280E: How the Cannabis Industry Got Here

As cannabis businesses brace for potential tax relief should the plant be rescheduled, a look at the origins of IRC Section 280E and why it applies to legal, state-level cannabis companies.

8 Internal Controls That Can Protect Your Cannabis Company

Established and continually tested checks and balances throughout your operation help prevent fraud, regulatory woes, litigation, and other serious threats to your business.

Opinion: HHS Rescheduling Recommendation is 'About Damn Time'

The U.S. Department of Health and Human Services recognition that cannabis should no longer be classified in the same category as heroin is an event to be celebrated. But the trajectory of U.S. policy deserves to be mourned.

Opinion: Rescheduling Is Recriminalizing, Descheduling Is Decriminalizing

President of cannabis genetics company DNA Genetics, Rezwan Khan, weighs in on Biden's cannabis policy reform plan and how rescheduling or descheduling the plant would impact the industry.

What Cannabis Brands Can Learn From Craft Beer About Product Development and Brand Management: 4 Tips

After spending more than two decades with The Boston Beer Company, Jay O’Malley, vice president of marketing and research development for MariMed, says cannabis brands and their buyers are growing up together, leaving plenty of uncontested market space where companies can innovate and create demand.

Scale Your Cannabis Cultivation Business With Efficiency In Mind

In times of price compression and increasing production costs, resource efficiency can make or break a cultivation business

Page 1 of 8

Next Page